Reports documenting the presence and impact of pulmonary hypertension (PH) complicating lung disease date back to the early 1980s. Ever since effective therapies for group 1 pulmonary arterial hypertension started to emerge in the 1990s with IV epoprostenol, through the early 2000s with the endothelin receptor antagonists and PDE-5 inhibitors, there has been increasing interest in the potential role of these therapies for PH beyond group 1 disease (1)...

• SARS-1, MERS, SARS-2 and more: are coronavirus infections an ubiquitous part of our lives? Albert Osterhaus
• Endothelitis and aberrant angiogenesis – mechanisms of COVID-19 induced vascular injury, Danny Jonigk
• Venous thromboembolism in COVID-19: Prevalence and clinical picture, Stavros Konstantinides
• ACE-II receptors – Modulation of PVD in COVID-19? Anna Hemnes
• Tricuspid regurgitation, as proxy for acute pulmonary hypertension, and its association with short-term outcome in severe Covid-19, Claes Frostell 
• Venous and arterial thromboembolism in COVID-19: a systematic review with meta-analysis, Vicky Mai

• Health and wearables: Is this the dawn of a new age for cardiovascular medicine? Martin Cowie
• Professor Sheila Glennis Haworth Memorial Lecture - Translational Research on PAH, Jason Yuan 
• Biomarker Analysis of the PULSAR Study: An Ongoing Phase 2, Double-Blind, Placebo-Controlled, Randomized Study to Compare the Efficacy and Safety of Sotatercept (ACE-011) Versus Placebo When Added to Standard of Care for the Treatment of PAH, Marc Humbert
• Switching from PDE5i to riociguat in patients with PAH: The REPLACE study, Raymond Benza
• A diagnostic miRNA signature for PAH using a consensus machine learning approach (Rupert Swift Award 2021), Niamh Errington

• The view of the World Heart Federation (WHF), Fausto Pinto
• Update on the Global Burden of PH Project of the Institute for Health Metrics and Evaluation (IHME), Sophia Emmons-Bell
• PVRI GoDeep: Perspectives of a global meta-registry, Werner Seeger
• Mortality of idiopathic/hereditary and connective tissue disease-associated pulmonary arterial hypertension: the data from first single center prospective registry in Indonesia, Anggoro Budi Hartopo
• Triple therapy in pulmonary arterial hypertension in an expert centre in Mexico City. Real-life results, Humberto Garcia-Aguilar